简
繁
EN
简
繁
EN
Home
Latest
Finance
IPO
ETF
Technology
Overseas
Research
HOME
·
JUNSHI BIO
Junshi Biosciences (01877.HK): Toripalimab NSCLC Indication Supplemental Application Accepted; Expanded from Stage IIIA-IIIB to Stage II-III
Tags：
JUNSHI BIO
01877.HK
2026-07-21
Junshi Biosciences (01877.HK): Signs Licensing Agreement with Fosun Wampo; Receives RMB215 Million Upfront and Up to RMB1.125 Billion Milestones
Tags：
JUNSHI BIO
01877.HK
2026-07-01
JUNSHI BIO(01877.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at loss of CNY 20.56 million, loss narrowed by 91.24% YoY
Tags：
JUNSHI BIO
01877.HK
narrow losses
2026-04-28
Featured News
Research
Frost & Sullivan and LeadLeo Release Landmark 2026 AI Agent Report; YouLianCloud Named Among the Chinese Agents with the Greatest Global Development Potential
Finance
SILVER GRANT INTERNATIONAL (00171.HK): Appointment of Liang Tingyu as Chief Financial Officer, Company Secretary and Authorised Representative
Finance
Milan Station (01150.HK): Total Disposal of 24.09 Million BFB Health Shares for Gross Proceeds of Approximately HK$11.24 Million
Finance
Esprit Holdings (00330.HK): Expected H1 Loss of Approximately HK$39 Million
Finance
DAIDO GROUP LIMITED (00544.HK): Completion of Subscription for 10 Million New Shares
Finance
China General Education Group (02175.HK): Resignation of Executive Director Zhang Zhonghua, Tian Yan Appointed as Successor
Finance
Boyaa Interactive (00434.HK): Expected H1 Loss of Approximately HK$790‑800 Million
Finance
China Merchants Securities (06099.HK): Resignation of Non‑executive Director Li Delin
Finance
Sang Hing Holdings (International) Limited (01472.HK): Joint Venture Awarded Hong Kong Tung Chung Infrastructure Project with Contract Sum of Approximately HK$689 Million
Finance
Saint Bella (02508.HK): Expected H1 Revenue Growth of Not Less Than 35% and Adjusted Net Profit Growth of Not Less Than 54%
Scan QR Code
Download App
